Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subodh Verma

Showing results (491-500 of 616) with videos related to

Pageof 62
Sort By:
JACC. Cardiovascular Imaging|January 17, 2021
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery DiseaseTamique Mason, Otavio R Coelho-Filho, Subodh Verma, et al.
Circulation|November 11, 2023
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort AnalysisKershaw V Patel, Matthew W Segar, David C Klonoff, et al.
Journal of Cardiac Failure|November 27, 2024
Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trialsKieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
JAMA Cardiology|February 17, 2021
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection FractionDavid D Berg, Pardeep S Jhund, Kieran F Docherty, et al.
Nature Medicine|August 31, 2025
Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trialBarry A Borlaug, Jeffrey M Testani, Mark C Petrie, et al.
Cell Metabolism|September 4, 2019
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes MellitusDavid A Hess, Daniella C Terenzi, Justin Z Trac, et al.
JACC. Heart Failure|September 16, 2025
Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF ProgramAmbarish Pandey, Dalane W Kitzman, Khaja M Chinnakondepalli, et al.
Journal of Cardiothoracic Surgery|May 4, 2019
SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449)Saswata Deb, Steve K Singh, Domingos de Souza, et al.
European Journal of Heart Failure|March 28, 2023
Health status across major subgroups of patients with heart failure and preserved ejection fractionTariq Jamal Siddiqi, Stefan D Anker, Gerasimos Filippatos, et al.
JACC. Heart Failure|June 15, 2024
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline CharacteristicsMikhail N Kosiborod, David Cherney, Kim Connelly, et al.
Pageof 62

Showing results (491-500 of 616) with videos related to

Sort By:
Pageof 62
JACC. Cardiovascular Imaging|January 17, 2021
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery DiseaseTamique Mason, Otavio R Coelho-Filho, Subodh Verma, et al.
Circulation|November 11, 2023
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort AnalysisKershaw V Patel, Matthew W Segar, David C Klonoff, et al.
Journal of Cardiac Failure|November 27, 2024
Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trialsKieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
JAMA Cardiology|February 17, 2021
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection FractionDavid D Berg, Pardeep S Jhund, Kieran F Docherty, et al.
Nature Medicine|August 31, 2025
Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trialBarry A Borlaug, Jeffrey M Testani, Mark C Petrie, et al.
Cell Metabolism|September 4, 2019
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes MellitusDavid A Hess, Daniella C Terenzi, Justin Z Trac, et al.
JACC. Heart Failure|September 16, 2025
Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF ProgramAmbarish Pandey, Dalane W Kitzman, Khaja M Chinnakondepalli, et al.
Journal of Cardiothoracic Surgery|May 4, 2019
SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449)Saswata Deb, Steve K Singh, Domingos de Souza, et al.
European Journal of Heart Failure|March 28, 2023
Health status across major subgroups of patients with heart failure and preserved ejection fractionTariq Jamal Siddiqi, Stefan D Anker, Gerasimos Filippatos, et al.
JACC. Heart Failure|June 15, 2024
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline CharacteristicsMikhail N Kosiborod, David Cherney, Kim Connelly, et al.
Pageof 62